We have been developing and manufacturing advanced optical instruments since 1982. Today, the majority of our business is the design and manufacture of high-quality medical devices. Approximately 8% of our revenue in fiscal year 2019 is from the design, manufacture and resale of optical products for military and defense and 13% for other industrial, non-medical products. Our medical instrumentation line includes traditional endoscopes and endocouplers as well as other custom imaging and illumination products for use in minimally invasive surgical procedures. Much of our recent development efforts have been targeted at the development of next generation endoscopes. Over the last ten years, we have funded internal research and development programs to develop next generation capabilities for designing and manufacturing 3D endoscopes and very small Microprecision™ lenses, anticipating future requirements as the surgical community continues to demand smaller and more enhanced imaging systems for minimally invasive surgery. Our unique proprietary technology in these areas, combined with recent developments in the areas of 3D displays and millimeter sized CMOS image sensors, has allowed us to begin commercialization of these technologies. Thus, approximately 30-40% of our revenues in each of the fiscal years 2017, 2018 and 2019 were derived from engineering and design services we performed for our customers to incorporate our technologies and capabilities into their medical device products. We believe that new products based on these technologies provide enhanced imaging for existing surgical procedures which help to enable development of many new medical device products and related medical procedures. Approximately 50-70% of our total revenues in fiscal years 2017, 2018 and 2019 were derived from the assembly and manufacture of endoscopic medical devises, sub-assemblies and optical components ordered by our customers and usually developed from the engineering and design services we perform for them. We expect sales revenue increases to come from the orders from our customers to manufacture the products we help them engineer and design.

Company profile
Ticker
POCI
Exchange
Website
CEO
Joseph Norman Forkey
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • GigCapital5 • Outset Medical ...
Former names
PRECISION OPTICS Corp INC, PRECISION OPTICS CORPORATION INC
SEC CIK
Corporate docs
IRS number
42795294
POCI stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
15 May 23
8-K
Departure of Directors or Certain Officers
9 May 23
8-K
Entry into a Material Definitive Agreement
30 Mar 23
10-Q
2023 Q2
Quarterly report
14 Feb 23
8-K
Departure of Directors or Certain Officers
5 Jan 23
CERT
Certification of approval for exchange listing
15 Nov 22
10-Q
2023 Q1
Quarterly report
14 Nov 22
8-A12B
Registration of securities on exchange
10 Nov 22
8-K
Precision Optics Announces Implementation of 1-for-3 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
2 Nov 22
8-K
Precision Optics Reports Preliminary First Quarter Fiscal Year 2023 Revenue
20 Oct 22
Transcripts
POCI
Earnings call transcript
2022 Q4
28 Sep 22
POCI
Earnings call transcript
2022 Q3
17 May 22
POCI
Earnings call transcript
2022 Q2
15 Feb 22
POCI
Earnings call transcript
2022 Q1
16 Nov 21
POCI
Earnings call transcript
2021 Q4
28 Sep 21
POCI
Earnings call transcript
2021 Q3
14 May 21
POCI
Earnings call transcript
2021 Q2
17 Feb 21
POCI
Earnings call transcript
2021 Q1
14 Nov 20
POCI
Earnings call transcript
2020 Q4
24 Sep 20
Latest ownership filings
3
Mahesh Lawande
9 May 23
SC 13D
Anania Peter V.
14 Apr 23
4
Peter V. Anania
14 Apr 23
SC 13D/A
DOLPHIN OFFSHORE PARTNERS LP
20 Mar 23
4
Joseph Norman Forkey
27 Jan 23
4
Peter H Woodward
18 Jan 23
4
Richard B Miles
18 Jan 23
4
Andrew J. Miclot
18 Jan 23
4
Peter V. Anania
18 Jan 23
3
Edward Kevin Dahill
13 Jan 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 22 | Jun 21 | Jun 20 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 612.10 k | 612.10 k | 612.10 k | 612.10 k | 612.10 k | 612.10 k |
Cash burn (monthly) | (no burn) | 18.29 k | 164.42 k | 37.04 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | 41.02 k | 368.72 k | 83.06 k | n/a | n/a |
Cash remaining | n/a | 571.08 k | 243.38 k | 529.03 k | n/a | n/a |
Runway (months of cash) | n/a | 31.2 | 1.5 | 14.3 | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jan 23 | Joseph Norman Forkey | Common Stock | By will or laws of descent | Acquire W | No | No | 0 | 4,974 | 0.00 | 120,847 |
16 Jan 23 | Peter V. Anania | Stock Options (Rights to buy) Common Stock | Grant | Acquire A | No | No | 6.26 | 13,334 | 83.47 k | 26,666 |
16 Jan 23 | Andrew J. Miclot | Stock Options (Rights to buy) Common Stock | Grant | Acquire A | No | No | 6.26 | 13,334 | 83.47 k | 60,000 |
16 Jan 23 | Richard B Miles | Stock Options (Rights to buy) Common Stock | Grant | Acquire A | No | No | 6.26 | 13,334 | 83.47 k | 62,133 |
News
Precision Optics Corp Q3 EPS $(0.07) Down From $(0.02) YoY, Sales $5.05M Up From $4.65M YoY
15 May 23
Earnings Scheduled For May 15, 2023
15 May 23
Precision Optics Announces $1.5M Follow-On Product Development Order For Single Use Urology Program
12 May 23
Precision Optics Appoints Mahesh Lawande As Chief Operating Officer, Effective April 24, 2023
17 Apr 23
Press releases
Precision Optics to Participate at Lytham Partners Spring 2023 Investor Conference on May 18, 2023
17 May 23
Precision Optics Reports Third Quarter Fiscal Year 2023 Financial Results
15 May 23
Precision Optics Announces $1.5 Million Follow-On Product Development Order for Single Use Urology Program
12 May 23
Precision Optics Corporation Schedules Third Quarter of Fiscal Year 2023 Conference Call for Monday, May 15, 2023
9 May 23
Precision Optics to Participate in the Planet MicroCap Showcase: VEGAS 2023 on April 26-27, 2023
21 Apr 23